That is essential, due to the fact that the way a protein in the human body folds figures out if a pharmaceutical will be able to bind to that protein and work. In other words, we need to know how these proteins fold if we want a drug to work. Historically, this has been an experimental process (biotech stocks jeff brown). And now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to develop drugs that do what they're created to do. This was a development practically nobody saw. But it's going to have profound implications for curing illness. I predict that Alpha, Fold will be 98% precise by the end of 2021.
And, naturally, there will be a lot of investment chances in this space, too. Shifting subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (jeff brown top biotech 2020). That said, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be amazed if it drew back maybe significantly before going greater - melania trump. I've been covering bitcoin for a very long time now. Among the very first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary recommendation, I entitled my report "What's the Big Offer With Bitcoin?" That reveals you where the conversation was at the time. We were mainly educating readers. However that's not the huge question any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche business. Mass, Mutual is a relied on 170-year-old organization. So believe about that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
And that's a big reason I'm bullish on it this year. future report. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I predict 2021 will be another record year in IPOs. There are numerous fantastic private business on the edge of striking the general public markets And I've been dealing with a brand-new way for you to invest even prior to these business go public.
This opportunity has actually been developing over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover all the information. Go right here to reserve your area for complimentary.
Emma Walsh here, handling editor of the Diary. Routine Diary readers understand that tech isn't our typical beat (jeff brown biotech stocks). And when it comes to tech investing, we leave it to the professionals. The good news is, we have numerous such specialists in our Rolodex. Our colleague Jeff Brown will recognize to our long time readers. He is one of the most accomplished tech investing specialists we know (last year). In fact, he had a number of triple-digit returns in his Brownstone Research study portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take a look at the big picture and forecast what's simply around the corner.
That consists of things like 5G networks, biotech, artificial intelligence, and a lot more. These trends are experiencing rapid development and creating amazing chances for financiers. I wish to make sure all our readers are prepared for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I have actually been covering for years now. jeff brown investor prediction. But despite what many readers may think, this is a trend that's just starting. Despite the fact that the COVID-19 pandemic interrupted supply chains in 2015, an outstanding 250 million 5G-enabled gadgets were still offered.
And all of this eventually led to Apple delaying the release of the 5G-enabled i, Phone 12 by two months (legacy report prediction). Losing two months of manufacturing and sales really impacts the number of 5G gadgets are sold in the calendar year. When you think about all of that, selling 250 million systems is impressive. More importantly, the delays brought on by the pandemic created a lots of suppressed need. And that need is now going to be pressed into 2021. In truth, I forecast that more than 500 million 5G devices will be shipped in 2021 - jeff brown biotech pick. Which's not my only 5G forecast When I've talked about 5G in the past, I have actually described its three different phases.
In Stage Two, 5G devices go on sale. 5G phones and other products begin to reach consumers. And in Stage 3, 5G services begin to be offered (jeff brown biotech genome sequencing). That's when we begin to see applications running on 5G networks. Consider things like huge multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will begin Stage 3 by this summertime. This starts something of a virtuous cycle: The majority of individuals do not really appreciate the innovation. But they will care if there are interesting applications that can just be accessed with a 5G phone.
That leads to more 5G apps being developed. In reality, 5G is going to open up a suite of incredible applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these technologies need 5G. The financial investment opportunities moving forward will be huge. Stepping far from 5G, the next crucial technology I predict in 2021 is CRISPR genetic editing. CRISPR means "clustered frequently interspaced short palindromic repeat." It's a mouthful. However it is among the most amazing advancements in biotechnology. At a high level, CRISPR is an innovation that can edit our hereditary makeup as if it were software application.
The program can crash or not work correctly. CRISPR uses a similar concept however with our hereditary code. "Typos" in our genome can result in disease. CRISPR can correct these "typos." For years, CRISPR was mainly a niche innovation that wasn't well comprehended. And during that time, there were truly only three business operating in this area. However things are altering. CRISPR is no longer simply theoretical. We're seeing actual outcomes. We're dealing with diseases and seeing that this innovation simply works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and delivering unbelievable returns. This whole industry is successfully a greenfield opportunity.
There's room for numerous business to exist in this space. jeff brown biotech stock pick for 2020. And there will be more. That's my forecast for CRISPR in 2021. I anticipate that two or three more genetic editing companies will hold their IPOs. Sticking with biotechnology, we are seeing fantastic things taking place at the merging of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its latest Alpha, Fold software can precisely anticipate the folding of a protein based solely on its amino acid series with 92. 4% accuracy. That is necessary due to the fact that the method a protein in the human body folds figures out if a pharmaceutical will have the ability to bind to that protein and work.
Historically, this has been a trial-and-error procedure. Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much simpler to create drugs that do what they're created to do. And here's my next prediction. I forecast that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one but numerous drug therapies produced using this technology. This was among those advancements that nearly no one discovered. However it's going to have profound ramifications for treating illness. And, obviously, there will be plenty of investment chances in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be shocked if it drew back maybe significantly prior to going higher. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever published was on bitcoin - tech stock. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anyone who followed my recommendation. However at the time of that preliminary recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That reveals you where the conversation was at the time.
However no one is asking that concern any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some little, specific niche business. exponential tech investor. Mass, Mutual is a 150-year-old institution. So believe about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another reward prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the information depends on date as of February 2021, but we could not independently validate this claim. Given Jeff Brown's past, he likely has a considerable net worth, but we can't hammer down a precise figure at this minute. Brown is best understood for his sage-like ability to select winning innovation stocks. He invested more than 25 years researching technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience provides him an excellent viewpoint on the marketplace. He's always on the hunt for brand-new opportunities, and he shares numerous of his best picks in the Near Future Report.
That's high praise, but it's not absurdly reasoned. Brown has an exceptional reputation as a stock-picker, and he effectively predicted some of the most significant financial occasions of the previous 20 years. Although he doesn't appear to launch his picks to the general public, the service's success is a direct indicator of Brown's stock-picking prowess. Nobody on Wall Street gets it ideal whenever, but Jeff Brown's accurate forecasts have actually earned him legions of devoted fans. That says a lot about his ability. The Near Future Report is published by Brownstone Research, a popular financial research study publisher. Brownstone Research offers several research services with a wide range of expertises - jeff brown genetic sequencing stock.
The company is likewise associated with Bonner & Partners, another well-respected research study publisher - biotech stock. On its site, Brownstone says its mission is to supply retail financiers with professional-grade research study: "For too long, the best investment research study has not been readily available to individual investors. It has actually been normally scheduled for investment banks, hedge funds, personal equity, and high-net-worth customers. first lady. The mission of Brownstone Research is to make that type of proprietary research available to any investors wanting to get an edge in the marketplaces. The goal is basic to provide special and successful financial investment research discovered no place else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also works as the company's Chief Investment Analyst.
With Brown assisting the ship, Brownstone Research is a powerhouse publisher with lots to offer its clients. After decades of consistent success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a home name throughout many of America. If you know even a little bit about the marketplace, you understand that he has a track record as a King Midas of sorts. exponential growth. Whatever he touches turns to gold! Jeff is aware of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big job.
In fact, Brown thinks S.A.V. jeff brown 1 biotech company. could be "the most significant trend of the 2020s, and he's not alone. Have a look at these quotes from other widely known S.A.V. bulls: Elon's next huge act will be marrying two cutting-edge innovations: synthetic intelligence and electrical cars. Musk hopes the combination will assist him develop the first fully-autonomous, self-driving automobiles ever. It's nothing except the automotive market's Holy Grail. As you know, electric vehicles and self-driving vehicle stocks have been substantial this year, however the Wall Street device has approved hype without much concrete outcome. In spite of a drastic increase in competitors over the past couple of years, Brown still thinks Musk has the very best opportunity of putting all of it together.
tech could be the magic string that ties all of it together. S.A.V. means Shared Autonomous Vehicle, and it could be the future of transport. Generally, this technology would enable you to rent your automobile as a self-governing, self-driving taxi when you're not utilizing it. You just leave the car and press a button on an app that tells the vehicle to "join the fleet." Next thing you understand, you're relaxing on your couch while your automobile shuttles ride-sharers around town. Most importantly, you get to keep a significant portion of the revenues. It sounds ridiculous, but it could be closed than you believe.